In April, 2025, Demis Hassabis, the Nobel Prize-winning CEO of Google DeepMind, appeared on the US television show 60 Minutes and suggested that all diseases could be curable with the help of ...

IO Biotech’s off-the-shelf cancer vaccine shows promise in melanoma with key data ahead, but funding risk limits near-term ...

The firm will test gedatolisib as a first-line treatment in patients with HR-positive, HER2-negative advanced breast cancer who are endocrine therapy resistant.

Pfizer Inc. has completed the previously announced global, ex-China, licensing agreement with 3SBio Inc., which grants Pfizer exclusive rights for the development, manufacturing and commercialization ...

Our team remains focused on driving enrollment and advancing this important program forward.” The MIRACLE study is a Phase 2B/3 clinical trial whereby data from the 2B portion will be combined with ...

A second phase 3 pivotal clinical trial investigating phentolamine ophthalmic solution 0.75% for the treatment of presbyopia met its primary and key secondary endpoints, according to a press ...

The phase 3, randomized, open-label, parallel-group clinical trial (Clinical Trial Registration Number: CTR20251345) of BAT8006 is designed to assess the efficacy of BAT8006 versus investigator's ...

Merck delivered a home run with its Phase 3 HYPERION trial, showcasing WINREVAIR’s prowess in battling pulmonary arterial hypertension (PAH). The study hit its primary endpoint by significantly ...

Compass Pathways says a single dose of its synthetic psilocybin significantly reduced depression symptoms in patients who haven’t responded to standard treatments, marking a key milestone in what ...

This trial further solidifies VSee’s position as a key player in the telerehab market, building on VSee’s prior role in Phase 1 and Phase 2 of this neurology study.

The first patient has been dosed in the IDeate-Prostate01 phase 3 trial evaluating the efficacy and safety of investigational ifinatamab deruxtecan (I-DXd) versus docetaxel in patients with ...

On June 18, Biogen announced the dosing of participants in the BRAVE study (NCT06953583), a global phase 3 clinical trial evaluating omaveloxolone (Skyclarys) in children aged 2 to younger than 16 ...